Skip to main content

Table 5 DFS according to MEG3 Polymorphisms

From: Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer

Gene SNP Genotype DFS HR (95% CI) P DFS Adjusted HR (95% CI) P
MEG3 rs10132552 TT 1   1  
TC + CC 0.193(0.042–0.884) 0.034* 0.127(0.22–0.728) 0.02*
rs941576 AA 1   1  
AG + GG 0.257(0.069–0.951) 0.042* 0.183(0.041–0.807) 0.025*
rs7158663 GG 1   1  
AG + AA 0.124(0.016–0.964) 0.046* 0.155(0.019–1.236) 0.078
rs10132552+ rs941576 TT + AA 1   1  
others 0.257(0.069–0.951) 0.042* 0.183(0.041–0.807) 0.025*
rs10132552+ rs941576 + rs7158663 TT + AA+GG 1   1  
Others 0.175(0.047–0.648) 0.009* 0.116(0.025–0.552) 0.007*
  1. Adjusted by ki67, tumor size, lymph nodes, hormone receptor, HER2 expression and age
  2. Abbreviations: HR hazard ratio; DFS Disease-free survival, HER2 human epidermal growth factor receptor −2
  3. *P < 0.05